Syndax Pharmaceuticals' stock surged 5.18% during intraday trading on Monday, following positive analyst coverage that boosted investor sentiment.
The price movement appears to be driven by Stifel Nicolaus analyst Stephen Willey maintaining a Buy rating on the company and setting a price target of $46.00. Analyst ratings and price target revisions often influence market perception and can trigger significant buying activity among investors.